tradingkey.logo

Spero Announces NDA Resubmission Of Tebipenem Hbr By Gsk To The FDA

ReutersDec 19, 2025 2:21 PM

- Spero Therapeutics Inc SPRO.O:

  • SPERO ANNOUNCES NDA RESUBMISSION OF TEBIPENEM HBR BY GSK TO THE FDA FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS

  • SPERO THERAPEUTICS INC - NDA SUBMISSION TRIGGERS $25 MILLION MILESTONE PAYMENT TO SPERO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI